Drugs / XS003
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07138352 | Oct 2024 → Jan 2025 | cancer | Xspray Pharma AB | Completed | No outcome recorded |
| Phase 1 | NCT02068898 | Dec 2013 → Mar 2014 | — | XSpray Microparticles | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02068898 ↗ |
| Known as | nilotinib | “This is a single-dose, open-label, randomized, crossover study to evaluate the comparative oral bioavailability of XS003 (nilotinib) Capsules 192 mg (4X 48 mg) of Xspray Pharma...” NCT07138352 ↗ |
| Route | Oral | “XS003 given as a single oral dose” NCT02068898 ↗ |